Restless legs syndrome: differential diagnosis and management with pramipexole

Francesca Brindani
Francesca Vitetta
Franco Gemignani
Department of Neurosciences, University of Parma, Italy

Abstract: Restless legs syndrome (RLS) is a condition characterized by discomfort at rest and urge to move focused on the legs. RLS may occur as an idiopathic, often hereditary condition (primary RLS), or in association with medical conditions (secondary RLS) including iron deficiency, uremia, and polyneuropathy. Current understanding of the pathophysiology of RLS points to the involvement of three interrelated components: dopaminergic dysfunction, impaired iron homeostasis, and genetic mechanisms. The diagnosis of RLS is made according to the consensus criteria by a National Institutes of Health panel: 1) an urge to move the legs, usually accompanied by uncomfortable sensations; 2) beginning or worsening during rest; 3) relieved by movement; and 4) worse, or only occurring, in the evening or at night. The differential diagnosis of RLS aims to: 1) distinguish RLS from other disorders with RLS-like symptoms and 2) identify secondary forms, with investigation of underlying diseases. The treatment of RLS demands a clinical evaluation to rule out and cure causes of secondary RLS, including iron supplementation when deficient, and to eliminate the triggering factors. The presence of neuropathy should be especially investigated in nonhereditary, late-onset RLS, in view of a possible treatment of the underlying disease. The first line treatment for idiopathic RLS is represented by dopamine agonists, in particular nonergot-derived ropinirole and pramipexole, whereas ergot dopamine agonists (cabergoline and pergolide) are no longer in first-line use given the risks of cardiac valvulopathy. Although no comparative trials have been published, a meta-analysis of pramipexole versus ropinirole suggests differences in efficacy and tolerability favoring pramipexole.

Keywords: restless legs syndrome, pramipexole, dopamine, agonists, small fiber neuropathy

Introduction

Restless legs syndrome (RLS) is a common, yet overlooked condition, mainly characterized by discomfort at rest and urge to move focused on the legs, first described by Willis\textsuperscript{1} in 1672, and recently re-defined by consensus criteria put forth by a National Institutes of Health (NIH) panel.\textsuperscript{2}

Most of the epidemiological studies that have employed adequate diagnostic criteria\textsuperscript{3} report prevalences of RLS (men and women combined) between 6% and 12%,\textsuperscript{4} when conducted in Western populations, but when distinguishing between the mere presence of RLS and clinically significant RLS (with symptoms frequent or severe enough to require treatment), the prevalence of this latter approaches 3%.\textsuperscript{5} The prevalence of RLS is distinctly lower in Asian populations, ranging from 0.1% in Singapore\textsuperscript{6} to 4.6% in elderly Japanese.\textsuperscript{7}

RLS may occur as an idiopathic, often hereditary condition (primary RLS), or in association with several medical conditions (secondary RLS) such as iron deficiency,\textsuperscript{8}
end-stage renal diseases,\(^9\) pregnancy,\(^10\) rheumatologic disorders,\(^11,12\) diabetes,\(^13,14\) as well as neurologic conditions such as Parkinson’s disease,\(^15\) spinal cord lesions,\(^16\) multiple sclerosis,\(^18\) and polyneuropathy.\(^18\)

The association of RLS with polyneuropathy is of particular interest from epidemiological, mechanistic, and diagnostic viewpoints, but is still controversial, in spite of extensive studies. Prevalence estimates of RLS in neuropathy are extremely variable, ranging from 5.2%\(^19\) to 54%.\(^20\)

In a series of 104 consecutive patients with miscellaneous neuropathies, we found a 29% prevalence of RLS, compared to 9% in controls.\(^18\) A prevalence of RLS of 54% was found in a selected series of patients with neuropathy with symptoms of pain or dysesthesia.\(^20\) On the contrary, in a recent controlled, double-blind study, the prevalence of RLS in neuropathy patients (12.2%) did not differ significantly from controls (8.2%), but in the subgroup of patients with hereditary neuropathy a higher prevalence of 19.4% was found.\(^21\)

Conflicting results may be due to methodological discrepancies in the design of the studies and in the assessment of RLS and of neuropathy, and variations in etiology of neuropathy between cohorts; in addition, it should be considered that, as polyneuropathy is usually an evolutive condition, the appearance or disappearance of RLS may be related to different phases of the disease. As it has been shown that RLS can be triggered by small fiber sensory neuropathy,\(^18,22-24\) it is expected that RLS prevalence in neuropathy will be higher when considering the forms with prevailing small fiber involvement, such as diabetic neuropathy.\(^14,25\)

In conclusion, we think that the prevalence of RLS in the course of polyneuropathy should be further assessed separately in different subtypes, segregated either by etiology or on the basis of preferentially involved nerve fiber population.

Current understanding of the pathophysiology of RLS points to the involvement of three interrelated components: dopaminergic dysfunction, impaired iron homeostasis, and genetic mechanisms.\(^26\) In particular, dopamine dysfunction plays a central role, as suggested by the early observation that dopaminergic drugs are highly effective in treating RLS.\(^27\)

Increasing data support the hypothesis that dysfunctions in dopaminergic pathway resides in the small diencephalospinal tract originating from the hypothalamic A\(^{11}\) nucleus,\(^16\) modulating the excitability of sensorimotor spinal circuits presumably subserving RLS.\(^28,29\)

Dysfunction of endogenous opioidergic circuits, possibly mediated by an interaction with the dopaminergic system, has been also implicated, based on the positive clinical response to opioidergic agents.\(^30\) Recently, in a PET study with an aspecific opioid receptor ligand, von Spiczak and colleagues found a negative correlation between RLS severity and the ligand binding in thalamus, amygdala, and anterior cingulated gyrus, structures involved in the medial pain system.\(^31\)

Alterations in iron metabolism probably intersect with dopamine signaling, for instance as a consequence of the role of iron as cofactor for tyrosine hydroxylase.\(^3\) Further, dopaminergic transmission may be affected by genetic factors, which however may also influence RLS at different neural levels, underlying changes of other motor and/or sensory structures possibly implicated in RLS.\(^20\) Finally, abnormal hyperexcitability of spinal circuits in RLS could be induced not only by impaired descending dopaminergic modulation, but also by changes in the spinal cord itself,\(^28\) or by abnormal peripheral inputs in peripheral nervous system (PNS) diseases.\(^18\)

**Diagnosis**

The diagnosis of RLS is made according to the NIH criteria,\(^2\) that is: 1) an urge to move the legs, usually accompanied or caused by uncomfortable or unpleasant sensations in the legs; 2) beginning or worsening during periods of rest or inactivity such as lying or sitting; 3) partially or totally relieved by movement such as walking or stretching; 4) worse in the evening or at night than during the day, or only occurring in the evening or night. In addition, supportive clinical features are considered (Table 1), which include, besides positive family history and response to dopaminergic therapy, the occurrence of periodic limb movements (PLMs) during wakefulness or sleep. PLMs are stereotyped rhythmic movements characterized by extension of the big toe and dorsiflexion of the ankle, which are recorded in standard polysomnography by surface electromyogram of anterior tibialis.\(^32\) A pathological number of PLMs (>5 PLMs/hour of sleep) is found in about 80% of RLS patients.\(^33\) and correlates with RLS severity.\(^34,35\) PLMs, however, are not specific for RLS, occurring in a variety of sleep disorders and also in normal people. PLMs can be a useful second level diagnostic tool in selected patients with uncertain RLS diagnosis who deserve instrumental investigations.

The diagnostic criteria have been summarized in a comprehensive definition of RLS as “movement-responsive quiescentogenic nocturnal focal akathisia usually with dysesthesias”.\(^36\)

There are two major steps in the differential diagnosis of RLS: 1) distinguishing RLS from other disorders with RLS-like symptoms; and 2) the individuation of secondary forms, with investigation of underlying diseases.
Conditions that resemble RLS (RLS “mimics”) include those with motor restlessness and those with a variety of leg pains or discomfort. Motor restlessness is characteristic for neuroleptic-induced akathisia, which, however, is usually generalized, with more stereotyped body and limb movements, while in RLS there is an urge to move a particular part of the body; patients with neuroleptic-induced akathisia do not experience sensory discomfort as an antecedent to motor restlessness, and often have no relief by movement. Nocturnal leg cramps are relieved with stretching or walking, but no urge to move is experienced, and painful muscular contraction is clearly unlike RLS sensations. Positional discomfort comes on with prolonged sitting or lying in the same position, but it is usually relieved by a simple change in position, unlike RLS, without a true circadian pattern, if not because during the night the rest increases the chances to maintain the same position. Volitional movements such as foot tapping and leg rocking, occurring in conditions of uneasiness, usually are not associated with sensory symptoms, discomfort, or conscious urge to move. Painful legs and moving toes involve mainly feet and toes, with slow writhing movements, in the absence of either conscious urge to move or circadian pattern. Various painful conditions, neurological or nonneurological, such as myelopathy, radiculopathy, peripheral neuropathy, lower limb arthritis, nighttime pain in the lower limbs in the course of congestive heart failure, may have symptoms that are worse at night, and cause sleep disturbances, but there is no urge to move and relief by movement.

The diagnosis of RLS secondary to, or associated with, other conditions represents a double-faceted process, as the problem may consist in the individuation of occult causes of apparently idiopathic RLS, or, on the contrary, in the recognition of overlooked RLS symptoms in the context of an overt neurological or systemic disease. The first occurrence is exemplified by an undisclosed iron deficiency, or by a mild neuropathy mainly manifesting with RLS; on the contrary, in the clinical context of severe diseases such as uremia, Parkinson disease, or multiple sclerosis, RLS may be disregarded in spite of its significant contribution to poor quality of life.

The role of polyneuropathy and its diagnostic work-up in RLS is controversial, in view of the uncertainty about its epidemiology, as discussed above. Although a statistically significant association of RLS with polyneuropathy has not been clearly demonstrated in overall populations of neuropathy, several reports suggest that RLS is frequent in distinct forms of polyneuropathy, especially when involving small sensory fibers, and this should be considered in a diagnostic approach.

As a practical point, patients with apparently idiopathic RLS of late onset and nonfamilial should be screened for polyneuropathy, especially when characterized by a sensory phenotype, and in particular for symptoms and signs of the small fiber series, and for possible causes of polyneuropathy if appropriate; on the other hand, we suggest that patients with polyneuropathy, especially of sensory type, should be questioned for symptoms of RLS as a treatable manifestation of the disease.

---

**Table 1 NIH diagnostic criteria of RLS**

<table>
<thead>
<tr>
<th>Essential criteria</th>
<th>Supportive clinical features</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. An urge to move the legs, usually accompanied or caused by uncomfortable or unpleasant sensations in the legs.</td>
<td>1. Positive family history of RLS.</td>
</tr>
<tr>
<td>2. The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting.</td>
<td>2. Response to dopaminergic therapy.</td>
</tr>
<tr>
<td>3. The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues.</td>
<td>3. Periodic limb movements during wakefulness or sleep (PLMs)*.</td>
</tr>
<tr>
<td>4. The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur in the evening or night.</td>
<td></td>
</tr>
</tbody>
</table>

**Associated features**

1. **Natural clinical course**: Onset age is variable, in patients with earlier onset (<50 years) the symptoms are insidious, while patients with later onset have a more aggressive course. RLS is usually a chronic disease with progressive clinical course; in mildest forms of RLS the clinical course can be static or intermittent.
2. **Sleep disturbances**: disturbed sleep is usually associated to RLS, this morbidity is however aspecific.
3. **Medical evaluation/Physical examination**: physical and neurological examination is generally normal (except for secondary RLS). Medical evaluation should be addressed to possible causes for secondary RLS.

**Abbreviations**: NIH, National Institutes of Health; PLMs, periodic limb movements; PLMw, periodic limb movement during wakefulness; RLS, restless legs syndrome.
Treatment

The treatment of RLS firstly demands a thorough clinical evaluation to rule out causes of secondary RLS, the most common of which is iron deficiency, and to eliminate the triggering factors, if any. A recommendation should be made to investigate the presence of neuropathy in selected cases, especially in nonhereditary, late-onset RLS, and/or in the presence of prominent sensory symptoms, in view of a possible treatment of the underlying condition, besides symptomatic therapy of RLS. It would be interesting that future trials explored if RLS associated with polynuropathy and/or with sensory phenotype will preferentially respond to particular drugs, such as antiepileptic drugs, rather than to dopaminergic therapy, as previously suggested.25

For primary RLS there are no treatments modifying the course of the disease available and the goal of different therapeutic strategy is to control the symptoms.

The European Federation of Neurological Sciences (EFNS) task force26 performed a review of the literature up to 2004 for the drug classes and interventions employed in the treatment of RLS and put forth guidelines for the management of RLS. According to EFNS guidelines, level A recommendations (effective in relieving the symptoms), were offered for cabergoline, gabapentin, pergolide, ropinirole, levodopa, and rotigotine by transdermal delivery, whilst other dopamine agonists (pramipexole, bromocriptine), valproate, oxycodone, carbamazepine, and clonidine were evaluated as probably effective (level B rating).

More recently, a task force commissioned by the Movement Disorder Society (MDS) performed an evidence-based review of the medical literature, which included studies published before December 31, 2006.30 The following drugs were considered efficacious: levodopa, ropinirole, pramipexole, cabergoline, pergolide, and gabapentin. Rotigotine, bromocriptine, oxycodone, carbamazepine, valproic acid, and clonidine were considered likely efficacious. Drugs that were considered investigational included dihydroergocriptine, lisuride, methadone, tramadol, clonazepam, zolpidem, amantadine, and topiramate, as well as magnesium, folic acid, and exercise. Intravenous iron dextran resulted likely efficacious for the treatment of RLS secondary to end-stage renal disease and investigational in RLS subjects with normal renal function, whereas oral iron was considered investigational, depending on the iron status of subjects.

According to both EFNS and MDS guidelines, the first line treatment for idiopathic RLS is represented by drugs that enhance dopaminergic neurotransmission.

Dopaminergic agents

L-Dopa/Benserazide or L-Dopa/Carbidopa

L-Dopa/Benserazide or L-Dopa/Carbidopa (100/25 mg or 200/50 mg at bedtime) are efficacious in controlling sensory and motor symptoms. As a consequence of its short plasma half-life (1–2 hours) there is a rapidly decreasing effect and RLS may reappear in the second half of the night, so that a second dose may be needed, usually three hours after bedtime.35

The limitation of L-Dopa consists mainly in the phenomenon of “augmentation”, a condition characterized by the worsening of RLS severity during RLS treatment.40 Diagnostic criteria for augmentation are shown in Table 2.

Prevalence of augmentation ranges from 18.6% to 72%34,35 and seems to be more frequent with higher doses and longer treatment duration.36 Dosages of 300–400 mg should not be exceeded.

Because of augmentation and the difficulty in controlling symptoms for the whole night in severe RLS (even with the combination of standard and sustained release formulation), L-Dopa is best used in patients with mild RLS or intermit-tent symptoms.

Since the use of L-Dopa is limited by its pharmacokinetic and pharmacodynamic characteristic, there has been a growing interest towards dopamine agonists.

Ergot-derived

Pergolide and cabergoline are effective in RLS in doses of 0.4–0.55 mg and 0.5–3 mg, respectively.34 However, because of their potential to induce fibrotic side effects with cardiac valvulopathy, they are not recommended in first-line use in RLS treatment and, if used, cardiopulmonary monitoring is required. There is insufficient evidence to make recommendation about bromocriptine, α-dihydroergocriptine, and lisuride.30

Nonergot-derived

Extensive data are available for ropinirole and pramipexole, which have approval for the indication idiopathic RLS in USA and European Union, whereas for rotigotine, although likely effective, more studies are needed. Rotigotine, formulated as a silicone-based transdermal patch (1–3 mg/24 h), improved the symptoms of RLS in two six-month trials in adults with idiopathic, moderate to severe RLS. Transdermal rotigotine was generally well tolerated, and improvements in RLS symptoms have been maintained in the long term. Further evaluations are required to ascertain if continuous
Pramipexole, a nonergoline dopamine agonist with a high selectivity for D(2) and D(3) receptors, is the last drug licensed for RLS treatment. Its efficacy was first tested in a single-night dose, confirming the superior reduction in the mean International RLS Study (IRLS) score, significantly lower incidence of nausea, vomiting, and dizziness for pramipexole compared to ropinirole.

The main difference between the two drugs seems to reside in earlier efficacy of pramipexole, evident after a single night dose. Although no comparative trials have been published, a recent meta-analysis of pramipexole versus ropinirole suggested differences in efficacy and tolerability favoring pramipexole. The indirect comparison showed a superior reduction in the mean International RLS Study Group Rating scale score, higher Clinical Global Impressions – Improvement scale response rate and significantly lower duration of relief from treatment. Pramipexole was effective in improving the symptoms of RLS, compared with placebo, in patients with moderate-to-severe primary RLS, with significant improvements observed within two nights of treatment, and was generally well tolerated. Significant benefits on objective measures of RLS motor symptoms, such as periodic leg movements, and on subjective measures of sleep were also demonstrated.

The main difference between the two drugs seems to reside in earlier efficacy of pramipexole, evident after a single night dose. Although no comparative trials have been published, a recent meta-analysis of pramipexole versus ropinirole suggested differences in efficacy and tolerability favoring pramipexole. The indirect comparison showed a superior reduction in the mean International RLS Study Group Rating scale score, higher Clinical Global Impressions – Improvement scale response rate and significantly lower incidence of nausea, vomiting, and dizziness for pramipexole compared to ropinirole.

**Pramipexole**

Pramipexole, a nonergoline dopamine agonist with a high selectivity for D(2) and D(3) receptors, is the last drug licensed for RLS treatment. Its efficacy was first tested in small or uncontrolled trials and further confirmed in more extensive studies, as summarized in Table 3.

Pramipexole improves both subjective symptoms of RLS and objective sleep parameters. In a double-blind, randomized, placebo-controlled, flexible-dose trial (0.125 mg; 0.25; 0.50; 0.75) on 345 patients, pramipexole improved significantly RLS severity and subjective sleep quality. In a polysomnographic double-blind, randomized, placebo-controlled study on 109 RLS patients (PRELUDE), pramipexole significantly reduced Periodic Limb Movements during time in bed Index (PLMI) and, at the dose of 0.50 mg, improved sleep efficiency (SE) and total sleeping time (TST).

Efficacy of pramipexole was demonstrated either after a single night dose, or in long-term therapy. Manconi and colleagues, in a single-blind, randomized, placebo-controlled study, compared subjective and polysomnographic parameters at the baseline and after one night on pramipexole at a single dose of 0.25 mg. They found a highly significant reduction in VAS score and a significant reduction of PLMS index (the primary outcome measure), and increment of sleep stage 2, sleep efficiency and time in bed on the pramipexole night.

Long-term efficacy has been recently confirmed in an open-label trial on 107 patients lasting 26 weeks (PRELUDE-extension) and in a telephone interview study on 195 RLS patients who took pramipexole at variable doses for at least one year. In a withdrawal trial, Trenkwalder and colleagues demonstrated very significant worsening of subjective RLS parameters in the group who discontinued pramipexole after six months of therapy. They also found an elevated number of dropouts (65%) in the placebo group, mainly due to lack of efficacy, compared to the drug group (9%).

Pramipexole is usually well tolerated. The discontinuation rate, about 20%, was similar in all the examined studies.

**Table 2 Augmentation diagnostic criteria**

<table>
<thead>
<tr>
<th>A. Basic features (all need to be met)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. The increase in symptom severity was experienced on five out of seven days during the previous week.</td>
</tr>
<tr>
<td>2. The increase in symptom severity is not accounted for by other factors such as a change in medical status, lifestyle or the natural progression of the disorder.</td>
</tr>
<tr>
<td>3. It is assumed that there has been a prior positive response to treatment.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>B and C. Additional features (one or both need to be met)</th>
</tr>
</thead>
<tbody>
<tr>
<td>B. Persisting (although not immediate) paradoxical response to treatment: RLS symptom severity increases some time after a dose increase and improves some time after a dose decrease.</td>
</tr>
<tr>
<td>C. Earlier onset of symptoms:</td>
</tr>
<tr>
<td>1. An earlier onset of at least four hours</td>
</tr>
<tr>
<td>or</td>
</tr>
<tr>
<td>2. An earlier onset (between two and four hours) occurs with one of the following compared to symptoms status before treatment:</td>
</tr>
<tr>
<td>a. Shorter latency to symptoms when at rest;</td>
</tr>
<tr>
<td>b. Extension of symptoms to other body parts;</td>
</tr>
<tr>
<td>c. Greater intensity of symptoms (or increase in periodic limb movements if measured by polysomnography (PSG) or the suggested immobilization test (SIT));</td>
</tr>
<tr>
<td>d. Shorter duration of relief from treatment.</td>
</tr>
</tbody>
</table>

Abbreviation: RLS, restless legs syndrome.
Table 3 Pramipexole trials in rLS

<table>
<thead>
<tr>
<th>Study design</th>
<th>Pramipexole administration</th>
<th>Outcome measure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Partinen 2006&lt;sup&gt;13&lt;/sup&gt;</td>
<td>• Fixed doses:</td>
<td>• Primary outcome: PLMI ↓</td>
</tr>
<tr>
<td>• Multicenter, double-blind, randomized, fixed-dose, placebo-controlled trial</td>
<td>• 0.125 mg</td>
<td>• Secondary outcome: PLMSI ↓; PLMVI ↓; PLM ↓; SL ↓; time in delta sleep ↓</td>
</tr>
<tr>
<td>• Randomization: 1:1:1:1</td>
<td>• 0.25 mg</td>
<td>• PLMAI →; SE →; TST →; IRLS ↓; ESS →; SSQ ↑; SF-36 ↑ (improvement in social function sub-score); PGI↑; CGI↑</td>
</tr>
<tr>
<td>• 109 patients with moderate–severe idiopathic rLS</td>
<td>• 0.50 mg</td>
<td></td>
</tr>
<tr>
<td>• Three week period</td>
<td>• 0.75 mg</td>
<td></td>
</tr>
<tr>
<td>Winkelman 2006&lt;sup&gt;13&lt;/sup&gt;</td>
<td>• Fixed doses:</td>
<td>• Primary outcome: IRLS ↓</td>
</tr>
<tr>
<td>• Double-blind, randomized, fixed-dose, placebo-controlled trial</td>
<td>• 0.125 mg (that could be increased by the physician to 0.25, 0.50 or 0.75 mg/day.)</td>
<td>• Secondary outcome: Improvement in PGI, CGI, VAS</td>
</tr>
<tr>
<td>• Randomization: 1:1:1</td>
<td>• 2–3 hours before bedtime</td>
<td></td>
</tr>
<tr>
<td>• 344 patients with moderate–severe idiopathic rLS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 12 week period</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oertel 2007&lt;sup&gt;11&lt;/sup&gt;</td>
<td>• Starting dose = 0.125 mg</td>
<td>• Primary outcome: IRLS ↓</td>
</tr>
<tr>
<td>• Double-blind, randomized, flexible-dose, placebo-controlled trial</td>
<td>• Individual optimized dosage (0.125, 0.25, 0.50 or 0.75 mg/die).</td>
<td>• Secondary outcome: Improvement in PGI, CGI, VAS</td>
</tr>
<tr>
<td>• Randomization: (placebo:pramipexole = 1:2)</td>
<td>• 2–3 hours before bedtime</td>
<td></td>
</tr>
<tr>
<td>• 345 patients with moderate–severe idiopathic RLS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Six week period</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trenkwalder 2006&lt;sup&gt;12&lt;/sup&gt;</td>
<td>• Mean dose = 0.59 ± 0.31 mg (range = 0.125–2.25 mg).</td>
<td>Questionnaire on efficacy:</td>
</tr>
<tr>
<td>• Multicenter, double-blind, randomized, flexible-dose, placebo-controlled</td>
<td>• Mean treatment duration = 30.5 ± 10.5 months</td>
<td>RLS severity ↓</td>
</tr>
<tr>
<td>withdrawal trial</td>
<td></td>
<td>• Difficulty in falling asleep ↓</td>
</tr>
<tr>
<td>• Randomization: 1:1</td>
<td></td>
<td>• Nocturnal awakenings ↓</td>
</tr>
<tr>
<td>• 130 RLS patients responding to pramipexole on a six-month period</td>
<td></td>
<td></td>
</tr>
<tr>
<td>were randomly assigned to receive placebo or to continue pramipexole for</td>
<td></td>
<td></td>
</tr>
<tr>
<td>three months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Montplaisir 2006&lt;sup&gt;13&lt;/sup&gt;</td>
<td>• Single dose of 0.25 mg</td>
<td>• Primary outcome: PLMS change index: ↓</td>
</tr>
<tr>
<td>• Telephone interview</td>
<td>• Administration time = 9.00 p.m.</td>
<td>• Secondary outcome: Sleep stage 2 ↑; time in bed, sleep efficiency (↑)</td>
</tr>
<tr>
<td>• 195 consecutives patients with idiopathic RLS who underwent pramipexole</td>
<td></td>
<td>• VAS (severity) = ↓</td>
</tr>
<tr>
<td>treatment for at least one year</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Manconi 2007&lt;sup&gt;41&lt;/sup&gt;</td>
<td>• Initial dose = 0.125 mg (titrated up to a maximum 0.75 mg)</td>
<td>• Primary outcome: IRLS ↓</td>
</tr>
<tr>
<td>• Single-blind, randomized, placebo-controlled, fixed-dose trial</td>
<td>• Administration time = 8.00–9.00 p.m.</td>
<td>• Secondary outcome: Improvement in CGI-I; PGI-I; ESS; SF-36; SSQ</td>
</tr>
<tr>
<td>• Randomization: 1:1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 32 patients with severe idiopathic RLS, never previously treated for RLS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Comparison of clinical and neuro-physiological parameters at the baseline</td>
<td></td>
<td></td>
</tr>
<tr>
<td>and after one night treatment.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Partinen 2008&lt;sup&gt;54&lt;/sup&gt;</td>
<td>• Initial dose = 0.125 mg</td>
<td></td>
</tr>
<tr>
<td>• Open label trial</td>
<td>• Administration time = 8.00–9.00 p.m.</td>
<td></td>
</tr>
<tr>
<td>• 26 week period</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
The incidence of adverse events was higher in the pramipexole group than in the placebo group, but not clearly dose-related. The most frequent adverse event was nausea, followed by fatigue, dizziness, headache, diarrhea, and nasopharyngitis, orthostatic hypotension and increased body weight. The severity of side effects was usually mild-to-moderate. An emerging concern with dopamine agonists is represented by compulsive behaviors, and in particular gambling.57

The prevalence of side effect seems to decrease significantly in long-term treatment (2.6%) (55 ddd) compared with early treatment.

Opioids

Opioids are used with increasing frequency in RLS therapy, especially in patients with significant daily symptoms and refractory RLS. However, only a few trials are available, concerning oxycodone (mean dose 15.9 mg),58 methadone (15.5 ± 7.7 mg/day),59 tramadol (50–150 mg/day).60 Although likely efficacious, they may cause a series of minor and major adverse effects: dizziness, nausea, vomiting, urinary retention, and constipation. Respiratory depression and addiction potential are major concerns. Augmentation has been reported with long-term tramadol treatment.61

Conclusions

RLS seems to be a quite common condition, although probably overlooked, and it may be disabling in severe cases. Thus improved diagnostic knowledge of RLS is warranted, in order to improve quality of life using available effective treatments in primary RLS, and, in addition, to individuate and treat underlying diseases in secondary RLS.

The mainstay of symptomatic treatment is represented by dopamine agonists, and in particular nonergot-derived. In this respect, available data suggest better efficacy and tolerability of pramipexole.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Willis T. De anima brutorum que hominis vitalis ac sensitiva est, exercitationes: duae: prior physiologiæ ejusdem naturam, partes, potestas et affectiones tradid: altera pathologiæ morbos qui ipsam, et sedem ejus primarium, nempe cerebrum et nervorum genus attingit, explicat, eorumque therapeias instituit. Oxford, two editions 1672 (quarto and octavo); London, R. Davis, 1672; Amsterdam, 1672, 1674; Lyon, 1676.


56. Trenkwalder C, Stiasny-Kolster K, Kupsch A, Oertel WH, Koester J, 
Rees J. Controlled withdrawal of pramipexole after 6 months of open-
label treatment in patients with restless legs syndrome. Mov Disord. 
2006;21(9):1404–1410.
57. Driver-Dunckley ED, Noble BN, Hentz JG, et al. Gambling and 
increased sexual desire with dopaminergic medications in restless legs 
58. Walters AS, Wagner ML, Hening WA, et al. Successful treatment of 
the idiopathic restless legs syndrome in a randomized double-blind trial 
59. Ondo WG. Methadone for refractory restless legs syndrome. Mov 
Disord. 2005;20:345–348.
60. Lauerna H, Markkula J. Treatment of restless legs syndrome with 
legs syndrome with long-term tramadol treatment. Mov Disord. 2007; 